6991-06-6

Upstream product

• 100-39-0 benzyl bromide 
• 58-63-9 Inosine 
• 890-38-0 2-deoxyinosine 
• 58-63-9 inosine 

Downstream Products

• 635723-78-3 7-benzyl-8-chloro-1,7-dihydropurin-6-one 
• 119584-60-0 ethyl (7-benzylhypoxanthin-1-yl)acetate 
• 119584-64-4 1-benzyl-4-isobutyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 
• 119584-59-7 4-amino-1-benzyl-5-(N-carboxymethyl)carbamoylimidazole 
• 119584-69-9 1-benzyl-4-isobutyl-7-methyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 
• 119584-67-7 1-benzyl-4,7-diethyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 
• 119584-62-2 1-benzyl-4-propyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 
• 119584-61-1 1-benzyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 
• 157162-80-6 1-benzyl-5-hydroxy-4,5,6,7-tetrahydroimidazo<4,5-e><1,4>diazepin-8(1H)-one 
• 157162-81-7 1-benzyl-4,5,6,7-tetrahydroimidazo<4,5-e><1,4>diazepin-8(1H)-one 

Relevant academic research and scientific papers

COMBINATION DRUG

The present invention provides pharmaceutical agents comprising a dipeptidyl peptidase IV (DPPIV) inhibitor and a biguanide agent in combination, which enhance the effects of active circulating glucagon-like peptide-1 (GLP-1) and/or active circulating glucagon-like peptide-2 (GLP-2).

Condensed imidazole derivatives

The present invention is related to compounds represented by the following formula, or salts or hydrates thereof wherein, T1 represents a 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, which is a monocyclic or bicyclic structure that may have one or more substituents; X represents a C1-6 alkyl group which may have one or more substituents, or such; Z1 and Z2 each independently represent a nitrogen atom or a group represented by the formula —CR2—; R1 and R2 independently represent a hydrogen atom, a C1-6 alkyl group which may have one or more substituents, or a C1-6 alkoxy group which may have one or more substituents, or such. These are novel compounds that exhibit an excellent DPPIV-inhibiting activity.

A one-pot preparation of 1-benzyl-2'-deoxyinosine from ionized 2'-deoxyinosine

A simple and one step synthetic method for the formation of 1-benzyl-2'-deoxyinosine was developed by direct benzylation of ionized 2'-deoxyinosine. Treatment of 2'-deoxyinosine, in the presence of NaOH, with benzyl bromide in 2,2,2-trifluoroethanol (TFE) or N,N-dimethylaetamide (DMA) gave 1-benzyl-2'-deoxyinosine in 35% and 80% yields, respectively.

Process for producing purine derivatives

Purine derivatives in which a desired substituent is introduced into the 9-position only are synthesized by first introducing an easily-removable substituent in the 7-position of a purine base of natural purine nucleosides obtained through fermentation or derivatives thereof, then hydrolyzing the ribose moiety to form purine derivatives having the substituent in the 7-position, subsequently introducing the desired substituent in the 9-position, and then removing the substituent in the 7-position.

Purines. LX. Dimroth rearrangement and concomitant hydrolytic deamination of 7-alkyl-1-methyladenines

The Dimroth rearrangement of 7-alkyl-1-methyladenines (8) to produce 7- alkyl-N6-methyladenines (9) (63-72% yield) has been found to be accompanied with unusual hydrolytic deaminations to give 7-alkyl-1-methyl-hypoxanthines (10) (1-3.5%) and/or 7-alkylhypoxanthines (11) (12-22%), when effected in boiling H2O for 4-70 h. Probable pathways leading to these by-products are proposed.

Cyclic homologs of xanthines. I. Imidazo[4,5-e][1,4]diazepine-5,8-diones

A useful synthetic approach to variously alkylated 4,5,7,8-tetrahydro-6H-imidazo[4,5-e][1,4]diazepine-5,8-diones is reported. These compounds are potentially interesting cyclic homologs of pharmacologically important alkylxanthines.